-
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
20 Mar 2025 20:15 GMT
… NBTXR3) for patients with lung cancer (NSCLC) to be … presented at the 2025 European Lung Cancer Conference (“ELCC”). ABSTRACT … Locoregional Recurrent Non-Small Cell Lung Cancer (“NSCLC”)
Saumil J. … therapy, with or without cetuximab, for the treatment …
-
Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C–Mutated NSCLC
28 Mar 2025 13:33 GMT
… fulzerasib (GFH925) and cetuximab (Erbitux) demonstrated efficacy with acceptable … advanced non–small cell lung cancer (NSCLC) harboring KRAS … during the 2025 European Lung Cancer Congress.1
At a … Presented at: 2025 European Lung Cancer Congress; March 26-29 …
-
Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFRC797S Mutation in Non-Small Cell Lung Cancer
27 Feb 2025 05:59 GMT
… cell lung cancer (NSCLC) and small cell lung cancer.1,2 … was combined with cetuximab,26 it demonstrated inhibitory … G, Pelosi E. Lung cancers: molecular characterization, clonal heterogeneity … non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113 …
-
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
21 Jan 2025 07:30 GMT
… 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation … study in non-small cell lung cancer brings us another step closer … radiation therapy, with or without cetuximab, for the treatment of patients …
-
The Targeted Pulse: Check Out Positive and Negative Updates in Head and Neck Cancer, and How the FDA is Handling Advancements in Lung Cancer Treatment
19 Jan 2025 19:53 GMT
… ), when compared with cetuximab (Erbitux), did not improve progression … the Fact Track for Lung Cancer Surgery
Injection abenacianine … existing deficits in lung cancer surgery by helping … [patients with] EGFR-positive lung cancer. These MARIPOSA results show …
-
Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report
17 Jan 2025 14:00 GMT
… , including non-small cell lung cancer (NSCLC), colorectal carcinoma ( … monoclonal antibodies (mAbs) (eg cetuximab, panitumumab, pertuzumab) and … during treatment of lung cancer and colorectal carcinoma … association and Taiwan Lung Cancer Society on the …
-
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
20 Feb 2025 21:48 GMT
… with Krazati (adagrasib) to Erbitux (cetuximab) continued to show meaningful … makes Krazati combined with Erbitux a potential treatment … primarily for patients with lung cancer; however, we see … much more frequently in lung cancer. Subsequently, we were …
-
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
14 Nov 2024 16:06 GMT
… therapeutic strategies available for lung cancer. Notably, combination therapies … alpha inhibitors, bevacizumab, and cetuximab, in an effort to … -L1 expression in human lung cancers. PLoS One. 2016; … p110α with RAS in lung tumor maintenance. Cancer Cell. 2013 …
-
Cancer Monoclonal Antibody Market Set to Reach USD 150.0 Billion, with a Healthy 3.68% CAGR Till Forecasts 2035
14 Apr 2025 09:58 GMT
… and chronic lymphocytic leukemia, while Cetuximab and Panitumumab are used in … growth factor receptor (EGFR). For lung cancer, PD-1 and PD-L1 … Outlook
Breast Cancer
Colorectal Cancer
Lung Cancer
Lymphoma
Leukemia
Cancer Monoclonal Antibody …
-
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
14 Sep 2024 08:50 GMT
… metastatic non-small cell lung cancer (NSCLC). After an … approximately 80-85% of lung cancers,2 with BRAF V600E … BRAFTOVI in combination with cetuximab and FOLFIRI chemotherapy in … American Lung Association. BRAF and lung cancer. Available at: https:…
About
© 1995-2025